Rapamycin may inhibit murine S180 sarcoma growth by regulating the pathways associated with autophagy and cancer stem...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Tumor growth is a complex process influenced by various molecular pathways.
• Rapamycin is an immunosuppressant drug known for its anti-proliferative effects.
• Understanding the mechanisms of rapamycin's anti-tumor activity is crucial for developing effective cancer therapies.

Purpose of the Study:

• To investigate the molecular mechanisms underlying rapamycin's inhibition of tumor growth.
• To examine the effects of rapamycin on cancer stem cell markers and autophagy in a murine sarcoma model.

Main Methods:

• Murine S180 sarcoma cells were used to establish tumors in mice.
• Mice were treated with varying doses of rapamycin or a vehicle control.
• Tumor volume was measured, and protein expression (mTOR, Beclin1, ULK1, LC3, Notch1, CD133, CD90) was analyzed using confocal microscopy and Western blotting.

Main Results:

• Rapamycin significantly inhibited tumor growth in a dose-dependent manner (30.1% and 48.8% inhibition).
• Rapamycin altered Beclin1, ULK1, and LC3-II/LC3-I ratio, indicating promotion of autophagy.
• Rapamycin suppressed mTOR, Notch1, CD133, and CD90 expression, suggesting inhibition of cancer stem cell phenotype.

Conclusions:

• Rapamycin-induced tumor growth delay is linked to the suppression of cancer stem cell markers (Notch1, CD133, CD90).
• Rapamycin promotes autophagy, evidenced by changes in mTOR, Beclin1, ULK1, and LC3-II/LC3-I ratio.
• These findings highlight dual mechanisms of rapamycin in inhibiting S180 sarcoma growth.